Concepts (164)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 7 | 2025 | 658 | 2.900 |
Why?
|
| Brazil | 22 | 2025 | 99 | 1.810 |
Why?
|
| Health Services Accessibility | 9 | 2024 | 554 | 1.580 |
Why?
|
| Early Detection of Cancer | 3 | 2024 | 315 | 1.470 |
Why?
|
| Antihypertensive Agents | 4 | 2019 | 171 | 1.230 |
Why?
|
| Pneumonectomy | 2 | 2025 | 109 | 1.110 |
Why?
|
| Health Expenditures | 3 | 2020 | 122 | 1.080 |
Why?
|
| Cost Sharing | 4 | 2020 | 15 | 0.990 |
Why?
|
| Diabetes Mellitus | 6 | 2022 | 536 | 0.970 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2025 | 122 | 0.890 |
Why?
|
| Socioeconomic Factors | 4 | 2024 | 775 | 0.880 |
Why?
|
| Pain, Postoperative | 1 | 2025 | 161 | 0.850 |
Why?
|
| Pharmaceutical Services | 3 | 2018 | 31 | 0.780 |
Why?
|
| Interrupted Time Series Analysis | 6 | 2022 | 28 | 0.720 |
Why?
|
| Retrospective Studies | 15 | 2025 | 6533 | 0.720 |
Why?
|
| Commerce | 2 | 2019 | 56 | 0.690 |
Why?
|
| Hypoglycemic Agents | 3 | 2019 | 214 | 0.690 |
Why?
|
| Drug Costs | 3 | 2017 | 56 | 0.690 |
Why?
|
| Health Policy | 4 | 2019 | 187 | 0.690 |
Why?
|
| Hypertension | 4 | 2020 | 590 | 0.660 |
Why?
|
| Financing, Government | 1 | 2020 | 30 | 0.650 |
Why?
|
| Analgesics, Opioid | 1 | 2025 | 533 | 0.650 |
Why?
|
| Costs and Cost Analysis | 1 | 2020 | 102 | 0.640 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 1589 | 0.640 |
Why?
|
| Smoking | 1 | 2024 | 864 | 0.620 |
Why?
|
| Pharmaceutical Preparations | 3 | 2015 | 123 | 0.600 |
Why?
|
| Drug Prescriptions | 2 | 2025 | 168 | 0.600 |
Why?
|
| Opioid-Related Disorders | 1 | 2025 | 491 | 0.570 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2017 | 25 | 0.560 |
Why?
|
| Drug Industry | 1 | 2017 | 39 | 0.540 |
Why?
|
| Humans | 34 | 2025 | 62687 | 0.470 |
Why?
|
| Incidence | 5 | 2025 | 1367 | 0.460 |
Why?
|
| Aged | 12 | 2025 | 14254 | 0.450 |
Why?
|
| Education, Continuing | 1 | 2014 | 24 | 0.450 |
Why?
|
| Capacity Building | 1 | 2014 | 21 | 0.450 |
Why?
|
| Insurance, Health | 1 | 2015 | 151 | 0.440 |
Why?
|
| Medication Adherence | 1 | 2015 | 196 | 0.440 |
Why?
|
| Education, Distance | 1 | 2014 | 34 | 0.440 |
Why?
|
| Female | 17 | 2025 | 32495 | 0.430 |
Why?
|
| National Health Programs | 4 | 2019 | 19 | 0.420 |
Why?
|
| Middle Aged | 14 | 2025 | 17365 | 0.410 |
Why?
|
| Delivery of Health Care | 3 | 2022 | 429 | 0.400 |
Why?
|
| Male | 15 | 2025 | 29487 | 0.400 |
Why?
|
| Acute Disease | 1 | 2013 | 670 | 0.370 |
Why?
|
| Robotic Surgical Procedures | 2 | 2025 | 141 | 0.360 |
Why?
|
| Health Personnel | 1 | 2014 | 363 | 0.340 |
Why?
|
| Primary Health Care | 2 | 2022 | 685 | 0.330 |
Why?
|
| Malaria | 1 | 2011 | 121 | 0.320 |
Why?
|
| Drugs, Essential | 2 | 2018 | 2 | 0.290 |
Why?
|
| Adult | 9 | 2025 | 16629 | 0.290 |
Why?
|
| Risk Factors | 5 | 2024 | 5303 | 0.290 |
Why?
|
| Pandemics | 2 | 2025 | 663 | 0.290 |
Why?
|
| Attitude of Health Personnel | 2 | 2014 | 587 | 0.270 |
Why?
|
| Drugs, Generic | 3 | 2019 | 18 | 0.260 |
Why?
|
| Honduras | 3 | 2015 | 3 | 0.260 |
Why?
|
| Guatemala | 3 | 2015 | 4 | 0.260 |
Why?
|
| Nicaragua | 3 | 2015 | 17 | 0.260 |
Why?
|
| Longitudinal Studies | 3 | 2020 | 1248 | 0.260 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 755 | 0.240 |
Why?
|
| Cross-Sectional Studies | 6 | 2018 | 2540 | 0.240 |
Why?
|
| Prevalence | 3 | 2024 | 1345 | 0.240 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2025 | 61 | 0.230 |
Why?
|
| Politics | 1 | 2025 | 34 | 0.230 |
Why?
|
| Databases, Factual | 2 | 2025 | 852 | 0.220 |
Why?
|
| Anastomotic Leak | 1 | 2024 | 35 | 0.220 |
Why?
|
| Sex Distribution | 1 | 2024 | 252 | 0.210 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2025 | 162 | 0.210 |
Why?
|
| Age Distribution | 1 | 2024 | 258 | 0.210 |
Why?
|
| Chronic Disease | 2 | 2018 | 748 | 0.210 |
Why?
|
| Esophagectomy | 1 | 2024 | 48 | 0.210 |
Why?
|
| Esophageal Neoplasms | 1 | 2024 | 83 | 0.200 |
Why?
|
| Fees, Pharmaceutical | 2 | 2015 | 5 | 0.200 |
Why?
|
| Smokers | 1 | 2023 | 119 | 0.200 |
Why?
|
| Acinetobacter baumannii | 1 | 2022 | 5 | 0.190 |
Why?
|
| Acinetobacter Infections | 1 | 2022 | 6 | 0.190 |
Why?
|
| Robotics | 1 | 2022 | 77 | 0.180 |
Why?
|
| Thoracic Surgery | 1 | 2022 | 70 | 0.180 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2022 | 140 | 0.180 |
Why?
|
| Mouth Neoplasms | 1 | 2021 | 34 | 0.180 |
Why?
|
| Tuberculosis | 1 | 2024 | 294 | 0.170 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2023 | 109 | 0.170 |
Why?
|
| Life Expectancy | 1 | 2020 | 34 | 0.170 |
Why?
|
| Program Evaluation | 2 | 2020 | 485 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 416 | 0.170 |
Why?
|
| Frailty | 1 | 2022 | 130 | 0.170 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2023 | 170 | 0.170 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 486 | 0.170 |
Why?
|
| Registries | 1 | 2024 | 872 | 0.170 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 108 | 0.170 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 352 | 0.170 |
Why?
|
| Government Programs | 1 | 2020 | 20 | 0.160 |
Why?
|
| Aortic Valve Stenosis | 1 | 2023 | 188 | 0.160 |
Why?
|
| Community Pharmacy Services | 1 | 2019 | 13 | 0.160 |
Why?
|
| Quality Improvement | 1 | 2024 | 435 | 0.160 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 933 | 0.160 |
Why?
|
| Public Health | 1 | 2021 | 186 | 0.150 |
Why?
|
| Young Adult | 3 | 2025 | 4633 | 0.150 |
Why?
|
| Mass Screening | 1 | 2024 | 686 | 0.150 |
Why?
|
| Longevity | 1 | 2019 | 113 | 0.140 |
Why?
|
| Quality of Health Care | 1 | 2022 | 517 | 0.140 |
Why?
|
| Losartan | 1 | 2017 | 19 | 0.140 |
Why?
|
| Renin-Angiotensin System | 1 | 2017 | 22 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 203 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 217 | 0.140 |
Why?
|
| Medicare | 1 | 2021 | 614 | 0.140 |
Why?
|
| Linear Models | 1 | 2017 | 409 | 0.130 |
Why?
|
| Lung | 1 | 2021 | 939 | 0.130 |
Why?
|
| United States | 3 | 2025 | 7725 | 0.120 |
Why?
|
| Drug and Narcotic Control | 1 | 2015 | 28 | 0.120 |
Why?
|
| Americas | 1 | 2014 | 6 | 0.110 |
Why?
|
| Professional Competence | 1 | 2014 | 91 | 0.110 |
Why?
|
| Public Sector | 2 | 2010 | 13 | 0.100 |
Why?
|
| Private Sector | 2 | 2010 | 12 | 0.100 |
Why?
|
| Research | 1 | 2014 | 192 | 0.100 |
Why?
|
| Income | 1 | 2013 | 169 | 0.100 |
Why?
|
| Health Care Surveys | 1 | 2013 | 285 | 0.100 |
Why?
|
| Quality of Life | 1 | 2019 | 1221 | 0.090 |
Why?
|
| Cities | 2 | 2021 | 29 | 0.090 |
Why?
|
| Sex Factors | 1 | 2013 | 973 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2023 | 5403 | 0.090 |
Why?
|
| World Health Organization | 1 | 2009 | 34 | 0.080 |
Why?
|
| Adolescent | 2 | 2025 | 6172 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2024 | 2040 | 0.060 |
Why?
|
| Quality Indicators, Health Care | 1 | 2009 | 334 | 0.060 |
Why?
|
| Chloroquine | 1 | 2025 | 54 | 0.060 |
Why?
|
| Hydroxychloroquine | 1 | 2025 | 21 | 0.060 |
Why?
|
| Ivermectin | 1 | 2025 | 24 | 0.060 |
Why?
|
| Azithromycin | 1 | 2025 | 31 | 0.060 |
Why?
|
| Time Factors | 2 | 2025 | 3742 | 0.060 |
Why?
|
| Outpatients | 1 | 2025 | 141 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2025 | 497 | 0.050 |
Why?
|
| Stomach | 1 | 2024 | 85 | 0.050 |
Why?
|
| Portugal | 1 | 2023 | 3 | 0.050 |
Why?
|
| State Medicine | 1 | 2023 | 12 | 0.050 |
Why?
|
| Spatial Analysis | 1 | 2023 | 9 | 0.050 |
Why?
|
| Morbidity | 1 | 2022 | 113 | 0.050 |
Why?
|
| Elective Surgical Procedures | 1 | 2022 | 117 | 0.050 |
Why?
|
| Emergencies | 1 | 2022 | 115 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2025 | 1341 | 0.040 |
Why?
|
| Health Services | 1 | 2021 | 82 | 0.040 |
Why?
|
| Logistic Models | 1 | 2024 | 1273 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 63 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2025 | 476 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 392 | 0.040 |
Why?
|
| Infant | 1 | 2025 | 1602 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2025 | 1937 | 0.040 |
Why?
|
| Pharmacies | 1 | 2019 | 36 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2022 | 337 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 335 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2022 | 405 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 178 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2019 | 210 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2022 | 713 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2014 | 2648 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2022 | 1284 | 0.030 |
Why?
|
| Child | 1 | 2025 | 4444 | 0.030 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2015 | 42 | 0.030 |
Why?
|
| Suriname | 1 | 2014 | 1 | 0.030 |
Why?
|
| El Salvador | 1 | 2014 | 4 | 0.030 |
Why?
|
| Colombia | 1 | 2014 | 22 | 0.030 |
Why?
|
| Dominican Republic | 1 | 2014 | 25 | 0.030 |
Why?
|
| Evidence-Based Practice | 1 | 2014 | 83 | 0.030 |
Why?
|
| Health Services Research | 1 | 2014 | 270 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2023 | 5591 | 0.020 |
Why?
|